For example, a clinical trial involving TXNRD1 inhibitor auranofin has been enrolled in phase I/II clinical trials to treat chronic lymphocytic leukemia, non-small cell lung cancer, and ovarian, peritoneal, and fallopian tube cancers (www.clinicaltrials.gov, trial numbers NCT01419691, NCT01737502, NCT01747798, and NCT03456700). This evidence concerns the gene TXNRD1 and B-cell chronic lymphocytic leukemia.